Market Research Logo

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2018

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H2 2018

Summary

Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies a


Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
Bioncotech Therapeutics SL
Hemispherx Biopharma Inc
MultiCell Technologies Inc
Oncovir Inc
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis B vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCT-465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly-ICLC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PrEP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Oct 24, 2018: Hemispherx to Present at the Dawson James Securities 4th Annual Small Cap Growth Conference
Oct 23, 2018: Provention Bio announces completion of enrollment of Phase 1b clinical trial of PRV-300 in moderate-to-severe ulcerative colitis
Oct 22, 2018: Hemispherx Outlines Ampligen combination therapy clinical study strategy for the treatment of multiple cancers in letter to stockholders
Sep 18, 2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe
Aug 28, 2018: Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order
Aug 24, 2018: Hemispherx to present at the 20th annual Rodman & Renshaw Global Investment Conference
Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine
Jul 03, 2018: Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies
Jun 27, 2018: Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina
Jun 15, 2018: Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot
Jun 05, 2018: Hemispherx Announces New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment
May 31, 2018: Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors
Apr 17, 2018: Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs
Apr 04, 2018: Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients
Mar 05, 2018: Hemispherx to Present Ampligen at the 30th Annual ROTH Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bioncotech Therapeutics SL, H2 2018
Pipeline by Hemispherx Biopharma Inc, H2 2018
Pipeline by MultiCell Technologies Inc, H2 2018
Pipeline by Oncovir Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report